MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/neuonc/noae071

Медицинская библиотека · Neuro-oncology · 2024

Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatment.

Obrecht-Sturm Denise, Schömig Lena, Mynarek Martin, Bison Brigitte, Schwarz Rudolf, Pietsch Torsten, Pfister Stefan M, Sill Martin, Sturm Dominik, Sahm Felix, Kortmann Rolf-Dieter, Gerber Nicolas U, von Bueren André O, Fleischhack Gudrun, Schüller Ulrich, Nussbaumer Gunther, Benesch Martin, Rutkowski Stefan

СтатьяПеревод в очереди

Аннотация

BACKGROUND

This study aims at clarifying the impact of persistent residual lesions following first-line treatment for pediatric medulloblastoma.

METHODS

Data on 84 pediatric patients with medulloblastoma and persistent residual lesions on centrally reviewed magnetic resonance imaging (MRI) at the end of first-line therapy were analyzed.

RESULTS

Twenty patients (23.8%) had residual lesions in the tumor bed (R+/M0), 51 (60.7%) had distant lesions (R0/M+) and 13 (15.5%) had both (R+/M+). Overall response to first-line therapy was minor or partial (≥ 25% reduction, minor response [MR]/PR) for 64 (76.2%) and stable disease (SD) for 20 patients (23.8%). Five-year post-primary-treatment progression-free (pptPFS) and overall survival (pptOS) were superior after MR/PR (pptPFS: 62.5 ± 7.0%[MR/PR] vs. 35.9 ± 12.8%[SD], P = .03; pptOS: 79.7 ± 5.9[MR/PR] vs. 55.5 ± 13.9[SD], P = .04). Furthermore, R+/M + was associated with a higher risk for progression (5-year pptPFS: 22.9 ± 17.9%[R+, M+] vs. 72.4 ± 12.0%[R+, M0]; P = .03). Watch-and-wait was pursued in 58 patients, while n = 26 received additional treatments (chemotherapy only, n = 19; surgery only, n = 2; combined, n = 3; valproic acid, n = 2), and their outcomes were not superior to watch-and-wait (5-year pptPFS: 58.5 ± 7.7% vs. 51.6 ± 10.7% P = .71; 5-year pptOS: 76.3 ± 6.9% vs. 69.8 ± 9.7%, P = .74). For the whole cohort, 5-year pptPFS by molecular subgroup (58 cases) were WNT: 100%, SHH: 50.0 ± 35.4%, group-4, 52.5 ± 10.5, group-3 54.2 ± 13.8%; (P = .08).

CONCLUSIONS

Overall response and extent of lesions can function as surrogate parameters to predict outcomes in pediatric MB patients with persistent lesions after first-line therapy. Especially in the case of solitary persistent medulloblastoma MRI lesions, additional therapy was not beneficial. Therefore, treatment response, extent/kind of residual lesions and further diagnostic information need consideration for indication of additional treatments for persisting lesions.

Для цитирования: Obrecht-Sturm Denise, Schömig Lena, Mynarek Martin, Bison Brigitte, Schwarz Rudolf, Pietsch Torsten, Pfister Stefan M, Sill Martin, Sturm Dominik, Sahm Felix, Kortmann Rolf-Dieter, Gerber Nicolas U, von Bueren André O, Fleischhack Gudrun, Schüller Ulrich, Nussbaumer Gunther, Benesch Martin, Rutkowski Stefan. Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatment.. Neuro-oncology. 2024. DOI: 10.1093/neuonc/noae071.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.